Discounted for Pipeline Uncertainty, Not Profitability
Moderna trades at a discount because the market sees only pipeline hopes, not earnings power. Deep losses and ROIC at -18.2% keep the focus on risk. For this price, investors want more than promises. Only a major approval before 2028 could change the story.
Published by AssetNext · 2026-08-05
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-31 | Profile and price weak | 34 | -33.0% | -26.4% |
| 2026-07-31 | Profile and price weak | 34 | -33.0% | -25.0% |
| 2026-07-24 | Profile and price weak | 34 | -33.9% | -20.2% |
Break down MRNA's structural position across all peer dimensions with the interactive app.